Teriparatide in patients with osteoporosis and type 2 diabetes.

Saved in:
Bibliographic Details
Title: Teriparatide in patients with osteoporosis and type 2 diabetes.
Authors: Schwartz AV; Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th Street, Box 0560, San Francisco, CA 94158-2549, USA. Electronic address: aschwartz@psg.ucsf.edu., Pavo I; Eli Lilly Regional Operations, Koelblgasse 8-10 A-1030, Wien, Austria. Electronic address: pavo_imre@lilly.com., Alam J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: alam_jahangir@lilly.com., Disch DP; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: disch_damon@lilly.com., Schuster D; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: schuster_dara@lilly.com., Harris JM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: harris_jennifer_meyer@lilly.com., Krege JH; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: krege_john_henry@lilly.com.
Source: Bone [Bone] 2016 Oct; Vol. 91, pp. 152-8. Date of Electronic Publication: 2016 Jul 01.
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 8504048 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2763 (Electronic) Linking ISSN: 18732763 NLM ISO Abbreviation: Bone Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2763
DOI:10.1016/j.bone.2016.06.017